In the ever changing biotherapeutics landscape, antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) success hinges on more than simply antigen recognition. While the Fab region controls ...
Autoimmune drug development increasingly recognizes that the Fc-FcR axis is more than an effector mechanism; it is a controllable immunological node that bridges humoral and cellular responses. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results